Indivior | Sustainability Performance
A pharmaceutical company specializing in addiction treatments, particularly for opioid dependency, by offering a range of proprietary medications.
1994
United States
501 - 1,000 employees
Pharmaceuticals
$1B - 10B in revenue
$1M - 10M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#9967
Overallⓘ#2240
in United Statesⓘ#239
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Indivior paid a USD 600 million settlement in 2020 over allegations of fraudulent marketing of its opioid addiction treatment Suboxone to increase prescriptions.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
4-6
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.